{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T09:35:41Z","timestamp":1792920941751,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"DOI":"10.1007\/s40262-026-01711-8","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T15:05:52Z","timestamp":1792767952000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Predictive Value of Gastrin for the Absorption of Erlotinib in Patients with Non-Small Cell Lung Cancer"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2913-8989","authenticated-orcid":false,"given":"Niels","family":"Heersche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7827-939X","authenticated-orcid":false,"given":"Daan A. C.","family":"Lanser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2070-3614","authenticated-orcid":false,"given":"Sophie M.","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5398-6414","authenticated-orcid":false,"given":"Cornelis","family":"Kramers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1602-6195","authenticated-orcid":false,"given":"Marthe S.","family":"Paats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6105-182X","authenticated-orcid":false,"given":"Anne-Marie C.","family":"Dingemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1864-2151","authenticated-orcid":false,"given":"Ron H. N.","family":"van Schaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5667-5697","authenticated-orcid":false,"given":"Ron H. J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4594-3374","authenticated-orcid":false,"given":"G. D. Marijn","family":"Veerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"1711_CR1","doi-asserted-by":"publisher","first-page":"175883591881834","DOI":"10.1177\/1758835918818347","volume":"11","author":"K Hussaarts","year":"2019","unstructured":"Hussaarts K, Veerman GDM, Jansman FGA, van Gelder T, Mathijssen RHJ, van Leeuwen RWF. Clinically relevant drug interactions with multikinase inhibitors: a review. Ther Adv Med Oncol. 2019;11:1758835918818347. https:\/\/doi.org\/10.1177\/1758835918818347.","journal-title":"Ther Adv Med Oncol."},{"issue":"5","key":"1711_CR2","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1016\/S1470-2045(20)30069-3","volume":"21","author":"GDM Veerman","year":"2020","unstructured":"Veerman GDM, Hussaarts K, Jansman FGA, Koolen SWL, van Leeuwen RWF, Mathijssen RHJ. Clinical implications of food-drug interactions with small-molecule kinase inhibitors. Lancet Oncol. 2020;21(5):e265\u201379. https:\/\/doi.org\/10.1016\/S1470-2045(20)30069-3.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1711_CR3","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1016\/s1470-2045(13)70579-5","volume":"15","author":"RWF Van Leeuwen","year":"2014","unstructured":"Van Leeuwen RWF, Van Gelder T, Mathijssen RHJ, Jansman FGA. Drug\u2013drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol. 2014;15(8):e315\u201326. https:\/\/doi.org\/10.1016\/s1470-2045(13)70579-5.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1711_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.100880","volume":"8","author":"JL Raoul","year":"2023","unstructured":"Raoul JL, Moreau-Bachelard C, Gilabert M, Edeline J, Frenel JS. Drug-drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure. ESMO Open. 2023;8(1):100880. https:\/\/doi.org\/10.1016\/j.esmoop.2023.100880.","journal-title":"ESMO Open"},{"key":"1711_CR5","unstructured":"U.S. Food and Drug Administration. Drug Label for Erlotinib. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021743s14s16lbl.pdf. Accessed on Aug 8 2026."},{"issue":"1","key":"1711_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40262-020-00910-1","volume":"60","author":"GDM Veerman","year":"2021","unstructured":"Veerman GDM, Hussaarts KGAM, Peric R, Oomen-De Hoop E, Landa KD, Van Der Leest CH, et al. Influence of cow\u2019s milk and esomeprazole on the absorption of erlotinib: a randomized, crossover pharmacokinetic study in lung cancer patients. Clin Pharmacokinet. 2021;60(1):69\u201377. https:\/\/doi.org\/10.1007\/s40262-020-00910-1.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1711_CR7","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3109\/00365521.2015.1019918","volume":"50","author":"P Sipponen","year":"2015","unstructured":"Sipponen P, Maaroos H-I. Chronic gastritis. Scand J Gastroenterol. 2015;50(6):657\u201367. https:\/\/doi.org\/10.3109\/00365521.2015.1019918.","journal-title":"Scand J Gastroenterol"},{"issue":"9","key":"1711_CR8","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nrgastro.2013.101","volume":"10","author":"WL Neumann","year":"2013","unstructured":"Neumann WL, Coss E, Rugge M, Genta RM. Autoimmune atrophic gastritis--pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol. 2013;10(9):529\u201341. https:\/\/doi.org\/10.1038\/nrgastro.2013.101.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"1711_CR9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1146\/annurev.physiol.65.092101.142205","volume":"65","author":"P Christian","year":"2003","unstructured":"Christian P, Robert Z, Manfred G. Physiology of Gastric Enterochromaffin-Like Cells. Annu Rev Physiol. 2003;65(1):371\u201382. https:\/\/doi.org\/10.1146\/annurev.physiol.65.092101.142205.","journal-title":"Annu Rev Physiol"},{"issue":"1","key":"1711_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1152\/physrev.1995.75.1.155","volume":"75","author":"SJ Hersey","year":"1995","unstructured":"Hersey SJ, Sachs G. Gastric acid secretion. Physiol Rev. 1995;75(1):155\u201389. https:\/\/doi.org\/10.1152\/physrev.1995.75.1.155.","journal-title":"Physiol Rev"},{"issue":"1","key":"1711_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12876-023-02816-1","volume":"23","author":"N Nagasaki","year":"2023","unstructured":"Nagasaki N, Takigawa H, Ito M, Boda T, Kotachi T, Hayashi R, et al. Diagnostic performance of the normal range of gastrin calculated using strict criteria based on a combination of serum markers and pathological evaluation for detecting gastritis: a retrospective study. BMC Gastroenterol. 2023;23(1):167. https:\/\/doi.org\/10.1186\/s12876-023-02816-1.","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"1711_CR12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/01.md.0000236956.74128.76","volume":"85","author":"MJ Berna","year":"2006","unstructured":"Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore). 2006;85(6):295\u2013330. https:\/\/doi.org\/10.1097\/01.md.0000236956.74128.76.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"1711_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0016-5085(76)80093-5","volume":"71","author":"J Fahrenkrug","year":"1976","unstructured":"Fahrenkrug J, de Muckadell OBS, Hornum I, Rehfeld JF. The mechanism of hypergastrinemia in achlorhydria. Effect of food, acid, and calcitonin on serum gastrin concentrations and component pattern in pernicious anemia, with correlation to endogenous secretin concentrations in plasma. Gastroenterology. 1976;71(1):33\u20137.","journal-title":"Gastroenterology"},{"issue":"4","key":"1711_CR14","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s11938-015-0065-8","volume":"13","author":"J Phan","year":"2015","unstructured":"Phan J, Benhammou JN, Pisegna JR. Gastric hypersecretory states: investigation and management. Curr Treat Opt Gastroenterol. 2015;13(4):386\u201397. https:\/\/doi.org\/10.1007\/s11938-015-0065-8.","journal-title":"Curr Treat Opt Gastroenterol"},{"issue":"12","key":"1711_CR15","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1200\/jco.2015.65.2560","volume":"34","author":"RWF van Leeuwen","year":"2016","unstructured":"van Leeuwen RWF, Peric R, Hussaarts KGAM, Kienhuis E, Ijzerman NS, de Bruijn P, et al. Influence of the acidic beverage cola on the absorption of erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2016;34(12):1309\u201314. https:\/\/doi.org\/10.1200\/jco.2015.65.2560.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1711_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/jama.2024.21972","volume":"333","author":"World Medical Association","year":"2025","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human participants. JAMA. 2025;333(1):71\u20134. https:\/\/doi.org\/10.1001\/jama.2024.21972.","journal-title":"JAMA"},{"key":"1711_CR17","unstructured":"European Medicines Agency. ICH E6 (R2) good clinical practice\u2014scientific guideline; 2024."},{"key":"1711_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jpba.2019.04.031","volume":"172","author":"CL Braal","year":"2019","unstructured":"Braal CL, Veerman GDM, Peric R, Aerts JGJV, Mathijssen RHJ, Koolen SLW, et al. Quantification of the tyrosine kinase inhibitor erlotinib in human scalp hair by liquid chromatography-tandem mass spectrometry: pitfalls for clinical application. J Pharm Biomed Anal. 2019;172:175\u201382. https:\/\/doi.org\/10.1016\/j.jpba.2019.04.031.","journal-title":"J Pharm Biomed Anal"},{"key":"1711_CR19","unstructured":"U.S. Food and Drug Administration. Bioavailability and Bioequivalence Studies for Orally Administered Drug Products. https:\/\/www.fda.gov\/files\/drugs\/published\/Guidance-for-Industry-Bioavailability-and-Bioequivalence-Studies-for-Orally-Administered-Drug-Products---General-Considerations.PDF. Accessed on Aug 8 2026."},{"key":"1711_CR20","doi-asserted-by":"publisher","first-page":"13607","DOI":"10.2147\/CMAR.S285121","volume":"12","author":"J Dong","year":"2020","unstructured":"Dong J, Tong S, Shi X, Wang C, Xiao X, Ji W, et al. Progastrin-releasing peptide precursor and neuron-specific enolase predict the efficacy of first-line treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations. Cancer Manag Res. 2020;12:13607\u201316. https:\/\/doi.org\/10.2147\/CMAR.S285121.","journal-title":"Cancer Manag Res"},{"key":"1711_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113695","volume":"155","author":"GDM Veerman","year":"2022","unstructured":"Veerman GDM, Hurkmans DP, Paats MS, Oomen-de Hoop E, van der Leest CH, van Thiel ERE, et al. Influence of esomeprazole on the bioavailability of afatinib: a pharmacokinetic cross-over study in patients with non-small cell lung cancer. Biomed Pharmacother. 2022;155:113695. https:\/\/doi.org\/10.1016\/j.biopha.2022.113695.","journal-title":"Biomed Pharmacother"},{"key":"1711_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70166","author":"DW Huntjens","year":"2025","unstructured":"Huntjens DW, Bequignon OJM, Krens SD, Lowenberg M, Chamuleau MED, Molenaar RJ, et al. Artificial intelligence modelling of tyrosine kinase inhibitors at risk of malabsorption and bioavailability-enhancing strategies. Br J Clin Pharmacol. 2025. https:\/\/doi.org\/10.1002\/bcp.70166.","journal-title":"Br J Clin Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01711-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01711-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01711-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T09:01:53Z","timestamp":1792918913000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01711-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":22,"alternative-id":["1711"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01711-8","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"25 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":2,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients provided written informed consent for use of their data and materials. Patient data were used from the COLA and MERLOT studies, which were approved by the local ethics committee (Erasmus University Medical Center Rotterdam), registered under MEC14-046 and MEC 16-590, respectively. The MERLOT study was also registered in the Dutch Trial Registry (number NL5984; NTR6148). This study was conducted in accordance with the Declaration of Helsinki and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice guidelines.","order":4,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Every patient provided written informed consent for the original studies and for the use of their data in future analyses.","order":5,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study design: NH, CK, RHJM, GDMV. Research performance: NH, DACL, SME, MSP, AMCD, RHNvS, RHJM, GDMV. Data analysis: NH, DACL, GDMV. Writing: NH, DACL, RHJM, GDMV. All authors read and approved the final version of the manuscript.","order":6,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}